Scorr-Insert
X

Find Novel Oncology Drugs in Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IDE196,Binimetinib

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ideaya Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 18, 2020

            Details:

            IDEAYA and Pfizer will form a Joint Development Committee (JDC), and there will be joint decision making and data sharing of the clinical trial results between the parties.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fulvestrant

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 04, 2020

            Details:

            Eagle has obtained additional data on its pilot clinical study of its product candidate, EA-114, which has the potential to enhance estrogen receptor inhibition and improve patient outcomes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): METTL3

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: EcoR1 Capital

            Deal Size: $63.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing April 23, 2020

            Details:

            Proceeds from the financing will be used to advance the development of Accent’s novel therapies targeting RNA-modifying proteins (RMPs), including its lead programs METTL3 and ADAR1.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CUE-101,Pembrolizumab

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Cue Biopharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 20, 2020

            Details:

            Under the terms of the agreement, Cue Biopharma will conduct a Phase 1 study, KEYNOTE-A78, evaluating CUE-101 in combination with KEYTRUDA in first-line HPV+ advanced head and neck cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): REGN1979

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Zai Lab

            Deal Size: $190.0 million Upfront Cash: $30.0 million

            Deal Type: Licensing Agreement April 08, 2020

            Details:

            Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AAV-based gene therapy

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Gene therapy

            Partner/Sponsor/Collaborator: Daiichi Sankyo Co Ltd

            Deal Size: $225.0 million Upfront Cash: $200.0 million

            Deal Type: Licensing Agreement April 01, 2020

            Details:

            Ultragenyx granted Daiichi Sankyo license to intellectual property, including know-how and patent applications, with respect to its HeLa manufacturing platform for AAV-based gene therapy products.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cell and gene therapy

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Gene therapy

            Partner/Sponsor/Collaborator: The Invus Group

            Deal Size: $170.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing March 30, 2020

            Details:

            The financing will support advancement of clinical development with at least six cell and gene therapies from across ElevateBio's portfolio companies to enter clinical studies this year and into 2021.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rituximab

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: AzarGen Biotechnologies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 26, 2020

            Details:

            iBio plans to transfer its proprietary FastPharming Manufacturing System™ to AzarGen in South Africa for production of critical biological medicines for the African continent.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VY-M

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Vycellix

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 25, 2020

            Details:

            The companies will collaborate on the delivery of Vycellix’s novel RNA immunomodulator VY-M using Avectas’ cell engineering platform, Solupore®.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human mesenchymal stem/stromal cell therapy

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: RoosterBio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 17, 2020

            Details:

            Senti will apply its novel gene circuit technology to hMSCs produced by RoosterBio’s breakthrough CliniControl™ hMSC manufacturing platform.

            PharmaCompass